- Home
- NBY vs EDSA Comparison
NBY vs EDSA Comparison
Compare NBY & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- EDSA
- Stock Information
- Founded
- NBY 2000
- EDSA 2015
- Country
- NBY United States
- EDSA Canada
- Employees
- NBY N/A
- EDSA N/A
- Industry
- NBY
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- EDSA Health Care
- Exchange
- NBY Nasdaq
- EDSA Nasdaq
- Market Cap
- NBY 15.7M
- EDSA 17.5M
- IPO Year
- NBY 2007
- EDSA N/A
- Fundamental
- Price
- NBY $1.20
- EDSA N/A
- Analyst Decision
- NBY Strong Buy
- EDSA Strong Buy
- Analyst Count
- NBY 1
- EDSA 2
- Target Price
- NBY $0.85
- EDSA $13.00
- AVG Volume (30 Days)
- NBY 1.2M
- EDSA 110.6K
- Earning Date
- NBY 11-06-2025
- EDSA 08-08-2025
- Dividend Yield
- NBY N/A
- EDSA N/A
- EPS Growth
- NBY N/A
- EDSA N/A
- EPS
- NBY 0.41
- EDSA N/A
- Revenue
- NBY $9,781,000.00
- EDSA N/A
- Revenue This Year
- NBY $23.91
- EDSA N/A
- Revenue Next Year
- NBY $32.05
- EDSA N/A
- P/E Ratio
- NBY $3.52
- EDSA N/A
- Revenue Growth
- NBY 113.47
- EDSA N/A
- 52 Week Low
- NBY $0.46
- EDSA $1.55
- 52 Week High
- NBY $4.44
- EDSA $4.49
- Technical
- Relative Strength Index (RSI)
- NBY 40.93
- EDSA 67.27
- Support Level
- NBY $1.22
- EDSA $2.30
- Resistance Level
- NBY $1.64
- EDSA $2.82
- Average True Range (ATR)
- NBY 0.24
- EDSA 0.17
- MACD
- NBY -0.16
- EDSA 0.03
- Stochastic Oscillator
- NBY 0.38
- EDSA 100.00
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.